BridgeMD
New treatment option for Fatty Liver
Official title Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter
ClinicalTrials.gov ID: NCT06203548
What this study is testing
- What it's testing
- Background: Non-alcoholic fatty liver disease (NAFLD) affects 30% of the Asian adult population and is emerging as one of the important leading causes of liver cancer and cirrhosis. Although a number of biomarkersmany have been developed for the assessment of liver fat and fibrosis, most existing studies were cross-sectional in nature.
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Intrahepatic triglyceride content by MRI-PDFF ≥5%
- At least one metabolic risk factor out of (1) body-mass index ≥23 kg/m2, (2) waist circumference ≥90 cm in men and ≥80 cm in women, (3) fasting...
- Provide informed written consent
You likely can't join if
- Positive hepatitis B surface antigen or anti-hepatitis C virus antibody, or history or evidence of other liver diseases
- Alcohol consumption \>30 g per day in men or \>20 g per day in women
- Liver decompensation, as evidenced by total bilirubin \>50 µmol/L (except in patients with documented Gilbert's syndrome), platelet count \ 1.3 times...
- Contraindications to MRI examination such as claustrophobia or the presence of metallic implants
- History or presence of hepatocellular carcinoma
- History of other malignancies, unless in complete remission for more than 5 years
See the full eligibility criteria
- Intrahepatic triglyceride content by MRI-PDFF ≥5%
- At least one metabolic risk factor out of (1) body-mass index ≥23 kg/m2, (2) waist circumference ≥90 cm in men and ≥80 cm in women, (3) fasting plasma glucose ≥5.6 mmol/L, 2-hour post-load glucose ≥7.8 mmol/L...
- Provide informed written consent
- Positive hepatitis B surface antigen or anti-hepatitis C virus antibody, or history or evidence of other liver diseases
- Alcohol consumption \>30 g per day in men or \>20 g per day in women
- Liver decompensation, as evidenced by total bilirubin \>50 µmol/L (except in patients with documented Gilbert's syndrome), platelet count \ 1.3 times the upper limit of normal, albumin \<35 g/L, or history or presence...
- Contraindications to MRI examination such as claustrophobia or the presence of metallic implants
- History or presence of hepatocellular carcinoma
- History of other malignancies, unless in complete remission for more than 5 years
- History of liver transplantation or liver resection
- Significant co-morbidities that will likely limit a patient's participation in lifestyle intervention or attendance of study follow-ups
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, Hong Kong
Compensation & support
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, Hong Kong. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.